– USA, CA – Kronos Bio, Inc. (NASDAQ: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Dr. Taiyin Yang, Ph.D., to its board of directors.
Dr. Yang has more than four decades of experience in developing and manufacturing medicines in a variety of therapeutic categories.
“On behalf of the board of directors and senior management at Kronos Bio, I am pleased to welcome Taiyin to the board at this exciting time in our growth as a company. Taiyin is a highly respected and experienced business leader with a proven track record across product development, commercial manufacturing and quality operations. Her counsel and expertise will be invaluable as we continue to advance our pipeline programs into later clinical development and approach commercialization,” said CEO, Dr. Norbert Bischofberger.
The company also announced that Jakob Loven will not stand for re-election at the 2021 AGM.
Dr. Norbert Bischofberger commented: “I would also like to thank Jakob for his dedicated service to the company and his many contributions over the years to help us reach where we are today.”
About Dr. Taiyin Yang
Dr. Taiyin Yang currently serves as EVP, Pharmaceutical Development and Manufacturing at Gilead Sciences Inc., with responsibility for all the company’s investigational compounds and marketed products. Under her leadership, Gilead developed the world’s first HIV single-tablet regimen and advanced more than 25 compounds from early-stage development to commercialization, reaching millions of people around the world. Dr. Yang joined Gilead in 1993, became the SVP, Pharmaceutical Development and Manufacturing in 2005, and was appointed to her current role in 2015. Before joining Gilead, Dr. Yang worked at Syntex Corporation for more than a decade, where she contributed to the development and commercialization of more than 10 medicines.
“I am excited to join Kronos Bio’s board of directors,” said Dr. Yang. “I look forward to contributing to the company’s future growth alongside my fellow board members and company senior management to help advance truly innovative drug candidates that have the potential to transform the lives of people affected by cancer.”
In addition to Kronos Bio, Dr. Yang is currently a member of the board of directors of Kodiak Sciences. She serves as an executive sponsor of the Gilead Asian Interest Network and is a member of the Expert Scientific Advisory Committee of Medicines for Malaria Venture. This year, Dr. Yang became a fellow of the American Institute for Medical and Biological Engineering. Dr. Yang holds a B.S. in chemistry from National Taiwan University and a Ph.D. in organic chemistry from the University of Southern California.
About Kronos Bio, Inc.
Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer. The company focuses on targeting dysregulated transcription factors and the regulatory networks within cells that drive cancerous growth. Kronos Bio’s lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase in development for the frontline treatment of NPM1-mutated acute myeloid leukemia. The company is also developing KB-0742, an oral inhibitor of cyclin-dependent kinase 9, for the treatment of MYC-amplified solid tumors.
Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass.
For more information: https://kronosbio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
